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Immunosuppression has been sporadically discon-
tinued by noncompliant liver allograft recipients for 
whom an additional 4 1/2 years of follow-up is pro-
vided. These anecdotal observations prompted a pre-
viously reported prospective drug withdrawal pro-
gram in 59 liver recipients. This prospective series has 
been increased to 95 patients whose weaning was be-
gun between June 1992 and March 1996,8.4:4.4 (Sm 
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years after liver replacement. A further 4 112 years 
follow-up was obtained of the 5 self-weaned patients. 
The prospectively weaned recipients (93 livers; 2 liverl 
kidney) had undergone transplantation under immu-
nosuppression based on azathioprine (AZA. through 
1979), cyclosporine (CsA. 1980-1989), or tacrolimus 
(TAC. 1989-1994). In patients on CsA or TAC based 
cocktails. the adjunct drugs were weaned first in the 
early part of the trial. Since 1994, the T cell-directed 
drugs were weaned first. Three of the 5 original self-
weaned recipients remain well after drug·free inter-
vals of 14 to 17 years. A fourth patient died in a vehic-
ular accident after 11 years off immunosuppression. 
and the fifth patient underwent retransplantation be-
cause of hepatitis C infection after 9 drug·free years: 
their allografts had no histopathologic evidence of re-
jection. Eighteen (19%) of the 95 patients in the pro-
spective series have been drug free for from 10 months 
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to 4.8 years. In the total group, 18 (19%) have had 
biopsy proved acute rejection; 7 (7%) had a presumed 
acute rejection without biopsy; 37 (39%) are still wean-
ing; and 12 (13%, all well) were withdrawn from the 
protocol at reduced immunosuppression because of 
noncompliance (n=8), recurrent PBC (n=2), preg. 
nancy (n= 1), and renal failure necessitating kidney 
transplantation (n=I). No patients were formally diag· 
nosed with chronic rejection, but 3 (3%) were placed 
back on preexisting immunosuppression or switched 
from cyclosporine (CsA) to tacrolimus (TAC) because 
of histopathologic evidence of duct injury. Two pa· 
tients with normal liver function died during the trial, 
both from complications of prior chronic immunosup· 
pression. No grafts suffered permanent functional im· 
pairment and only one patient developed temporary 
jaundice. Long surviving liver transplant recipients 
are systematically overimmunosuppressed. Conse· 
quently, drug weaning, whether incomplete or com· 
plete, is an important management strategy providing 
it is done slowly under careful physician surveillance. 
Complete weaning from CsA·based regimens has been 
difficult. Disease recurrence during drug withdrawal 
was documented in 2 of 13 patients with PBC and 
could be a risk with other autoimmune disorders. 
The morbidity arising from the chronic use of antirejection 
medications is an incentive to establish the lowest possible 
level of immunosuppression necessary to maintain stable 
graft function. The rmding that complete freedom from im-
munosuppression was sporadically possible in long-surviving 
recipients of liver (1) and kidney allografts (2) prompted a 
prospective trial of drug weaning (3). Although it was shown 
that significant reductions in medication or their discontinu-
ance could be safely accomplished, the danger of consequent 
rejection has not been completely assessed and guidelines for 
judicious weaning need to be clarified. We present here fur-
ther observations on 3 cohorts of liver recipients: 5 who 
self-weaned many years ago (1), 59 who were in the prospec-
tive weaning trial of Ramos et a1. (3), and 36 who were 
subsequently entered. 
MATERIALS AND METHODS 
Case material. Historical cases: Five liver recipients who were 
12 112 to 18 213 years postoperative when they were studied in May 
1992 already had been drug free because of noncompliance for 5 to 11 
years; all had donor leukocyte microchimerism (l). One (OT 125) of 
the 5 was known at that time to have thrombosis of the hepatic 
artery. A further 4 112 year follow-up is available for 4 of these 5 
recipients; the fifth was killed in a vehicular aCCident. 
Prospective series: The emphasis of this report is on 95 patients 
whose controlled weaning was begun between June 1992 and April 
1996 after meeting the following criteria: ( 1) ;;:5 years posttransplan-
tation; (2) ;;:2 years without a documented rejection episode; (3) 
evidence of medical compliance: \ 4) availability of a cooperative local 
physician for follow-up; (5) absence of acute or chronic rejection on 
baseline liver biopsy; and (6) exclusion of other diagnoses such as 
vascular or biliary tract complications or recurrence of original dis-
ease. Thirty-one patients were s20 years old (pediatric cohort) at 
entry mto the study and 64 were between ~1 and 68 years old. 
The pretransplant diagnoses included chrome viral hepatitis 
'n= 13l. biliary atresia In=25l. autoimmune hepatitis In =41. primary 
~clerosmg cholangitis or primary biliary Cirrhosis I PBCl" 'n = 16l. 
• AbbreViations: ALT. alamne ammotransterase: AST. aspartate 
. Immotranslerase: .'-.ZA. azathiopnne: ('sA. ~yclosporme: GGTP. 
hepatoma (n=4). and a miscellaneous group (n=33) including alco. 
holic cirrhosis. cryptogenic cirrhosis, Budd-Chiari syndrome, toxic or 
secondary biliary cirrhosis, Wilson's disease. hemochromatosis, al· 
pha 1 antitrypsin deficiency, polycystic liver disease, and cystic fi· 
brosis. Of the 95 patients, 93 received liver allografts only. The other 
2 were given a simultaneous kidney graft from the liver donor. 
Baseline immunosuppression. Immunosuppression at the start of 
weaning consisted of AZA/PRED in 13 cases, CsAlPRED in 32, CsN 
AZAIPRED in 24, CsNAZA in 4, CsA alone in 11, TAC in 8, TAC/ 
PRED in 1, and TAC/AZA in 2. This heterogeneity was due to 'the 
performance of the transplantations in 3 successive eras in which 
cocktail immunosuppression was based on AZA (through 1979). CsA 
(1980-89), and TAC (1989-1994). In the first 8 months of 1989, CsA 
was the baseline drug, but it was replaced by TAC during the last 
half of that year. Except for the TAC era, initial triple drug therapy 
was used throughout the 30 year period of our program (Colorado! 
Pittsburgh), always involving PRED as the secondary drug, but with 
the variable use of AZA and ALG (or OKT3) as third or fourth agents 
(4). PRED was the only adjunct drug in most of the patients treated 
from the outset with TAC. 
ComplicatioT18 of immunosuppression. Preexisting complications 
of long-term immunosuppression in the prospective series included 
hypertension (n=32); renal insufficiency (n=27J; skin lesions or ma-
lignancy (n=12); neurologic symptoms or findings (n=4); infection 
(n=6); steroid-related complications (n=9) such as obesity, growth 
failure, and bone disease; and diabetes (n=9). Thirty-seven patients 
had multiple complications attributable to their immunosuppres-
sion. 
Weaning protocol. At the beginning of the prospective trial (3), 
AZA was the first drug weaned when it was part of cocktail therapy 
(either 2 or 3 drugs). Before complete PRED weaning, corticotropin 
stimulation testing was done to detect adrenal insufficiency. The 
baseline immunosuppressive agent (CsA, AZA, or TAC) was with-
drawn last by 25% increments at 1-2-month intervals as long as 
hepatocellular enzyme results remained stable. After the greater 
difficulty of weaning from CsA based immunosuppression and also in 
an effort to minimize cumulative nephrotoxicity, emphasis was 
shifted to primary weaning of CsA (or, when applicable, TAC), fol· 
lowed later by AZA and/or PRED. In addition. weaning was done 
more gradually in the later period in an effort to reduce the incidence 
of rejection. 
Monitoring: Liver injury tests consisting of AST, ALT, GGTP. and 
serum bilirubin were monitored weekly after changes in drug dos-
age. If liver function abnormalities developed, a liver biopsy was 
obtained when permitted by the patient or family. Treatment for 
documented cellular rejection consisted of return to the medications 
preceding the last dose reduction, with or without pulse steroid 
therapy. A switch to TAC therapy in patients previously on other 
baseline therapy was reserved for biopsy proved moderate or severe 
ACR or evidence of developing chronic rejection. The staging of acute 
(5) and chronic rejection (6) has been described elsewhere. The cri-
teria of van Hoek et a1. for a formal diagnosis of chronic rejection 
were used. 
Adult and pediatric stratification: The mean time from transplan· 
tation to the start of weaning in the whole group was 8.4 years:!:4.4 
(range: 1.7-25.0 yr). For adult patients. the mean was 9.13 years. 
and for pediatric patients it was 6.64 years (PsO.008, t testl. 
StatistLcal analysis. Continuous variables are presented as the 
mean:!: SD, and categorical variables as proportions. The standard 
two-sample t test was used to test differences between means. while 
differences in proportions were tested using Pearson·s chi-square 
test or Fisher·s exact test (f testl if expected frequencies were less 
than live. The one-way analysis of variance was used instead of the 
two-sample t test when the number of groups to be compared was 
greater than two. 
~amma-fdutamvl transpeptldase; PRED. prednisone: PBC. prlmarv 
llliiarv CirrhOSIS; TAC. tacrohmus . 
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The cumulative probability of being weaned off immunosuppres-
sive therapy was computed using the Kaplan-Meier (product-limit) 
method. and probability curves compared by the log-rank (Mantel-
Cox) test. Patients who died, developed rejection. refused to observe 
the protocol. or are still weaning were censored. All tests were 
two-tailed. A P value less than 0.05 was considered statistically 
sipificant. 
RESULTS 
Graft loss and patient survival. Historical cases (n=5): 
Patient OT 125, who was drug free for 5 years with normal 
hepatic function in 1992 (1) despite a known hepatic artery 
thrombosis had subacute deterioration of allograft function 
beginning in 1995. She underwent successful liver retrans-
plantation in April 1996 at UCLA (Busuttil R). Study of the 
allograft at UCLA (and independently by Pittsburgh pathol-
ogists) showed that chronic hepatitis C was responsible for 
the graft loss, with no evidence of rejection. The allograft had 
been in place for 19 years, of which 9 were without immuno-
suppression. 
Patient OT 92 was killed instantly in an automobile acci-
dent on 5 November 1995, 17 112 years posttransplantation 
and 11 years after stopping drugs. His liver function and the 
coroner's report of the allograft were normal. 
The other 3 patients (OT 73, 150, and 169) are 18 213, 18, 
and 16 112 years posttransplantation. They continue to have 
normal allograft function after drug free intervals of 14, 17, 
and 15 years, respectively. 
Prospective trial (n=95): Two patients died during the 
study period of non-liver allograft-related causes, both with 
normal liver function. The first, who was still weaning, died 
of septic pulmonary complications of cystic fibrosis. The sec-
ond patient, who had been returned to baseline immunosup-
pression following an easily controlled mild acute cellular 
rejection, died of a pulmonary embolus following complica-
tions of a severe toe infection. It is noteworthy that these 
deaths were directly or indirectly attributable to the morbid-
ity of chronic immunosuppression. which the weaning proto-
col was designed to ameliorate. There were no other graft 
losses. 
Status of prospective weaning. Table 1 depicts the current 
status of the 95 patients prospectively weaned. Figure 1 
shows the results by age. The status of weaning is as follows. 
Complete: Eighteen <19%) of the 95 patients in the pro-
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FIGURE 1. Weaning trial results by age group. 
spective cohort have been drug free for 0.84 to 4.8 years. 
Seven of these recipients already were on low levels of im-
munosuppression at the first visit to the weaning clinic and 
had drugs stopped at that time. The 11 others were weaned 
over a mean period of 6.6 months. Their current liver func-
tion tests are summarized in Table 2. 
In progress: Currently 37 patients are in the uninter-
rupted process of drug weaning. The mean percentage de-
crease in baseline immunosuppression in these patients is 
shown in Table 3. 
Interrupted by rejection: Eighteen patients had weaning 
interrupted because of histopathologically confirmed rejec-
tion. Seven additional patients had weaning stopped because 
the diagnosis of rejection was suspected clinically, although 
not proved by biopsy. Finally, suspicion of incipient chronic 
rejection on biopsy prompted resumption of immune suppres-
sion in 3 cases. 
Withdrawal from protocol: Twelve patients were with-
drawn from the protocol due to noncompliance (n=8), preg-
nancy (n=1), renal failure requiring kidney transplantation 
(n=1), and recurrent PBC (n=2). The 8 excluded because of 
noncompliance were left at whatever level of treatment had 
TABLE 1. Prospective weaning trial results (n=95) 
Number of patients (%) 
Years from transplant to weaning 
start 
Mean=SD" 
Median (range) 
Time from weaning to off. rejection. 
or weaning interruption (months) 
Mean=SD 
Median (range) 
Follow-up (months) 
Mean=SDb 
Median (range) 
a P=O.901 (ANOVA). 
h As of 5·6-96 or patIent death . 
OfT Drugs 
18 (19%) 
8.3=5.4 
7.6 (1.8-21.6) 
5.9=5.9 
0.28 (0-31.7) 
34.5=11.2 
35.5 (10.1-57.2) 
Weaning in 
progress 
37 (39%) 
8.1=4.2 
7.8 (1.7-21.3) 
Not Applicable 
33.6=18.1 
19.6 ElK1~SKOF 
Rejection 
28 (29%) 
8.9=3.4 
8.7 (3.1-19.6) 
13.2=11.6 
9.4 \0.4-42.5) 
22.8=14.4 
25.3 (0.2--42.4) 
Weaning 
interrupted' 
12 (13%) 
8.5=6.0 
6.7 (1.8-25.0) 
12.0=8.3 
9.5 (2.6-27.2) 
. Because of noncompliance (n =/l) recurrent dIsease I PBC. n =;l). pregnancy t n = 1 I. and renal failure reqummr renal transplant t n'" II. 
-
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TABLE 2. Mean laboratory values ("'sm in patients (n=18) oifimmunosuppression 
Bilirubin (mgldll ASr (lUlL) ALT (IUIL) GGT (lUlL) Creatinine (mgldll" 
0.7=:0.37 
(range 0.3-1.4) 
39.7=:22 
(range 5-91) 
39.6=:26 
(range 9-101) 
45.7=:69 
(range 10-258) 
.78=:.34 
(range 0.3-1.5) 
a 1118 patients is dialysis dependent; the mean creatinine is for the other 17. 
TABLE 3. Reductions of individual immunosuppressive drugs in 37 patients with uninterrupted but still incomplete weaning 
Baseline (mglday) 
Current dosage (mglday) 
% Decrease 
Azathioprine 
59:29 
45:21 
13:33 
been reached at the time the decision to stop weaning was 
made. All 8 were well at the time and remain so. 
Results by immunosuppression regimen. There was no 
significant difference in the prospective trial in the rate of 
success when the baseline immunosuppressant was TAC or 
AZA (Fig. 2). However, there was a significant difference 
between these groups and all of the CsA-based regimens 
Em~lKMMPFK Figure 3 demonstrates the cumulative percent of 
patients off immunosuppression at one year postweaning. 
AZAIPRED-based patients were more likely to be off drugs at 
one year as compared with CsA-based patients (P=O.0007, 
log rank), TAC-based patients enjoyed a similar advantage 
(P=O.0031, log rank). 
Impact on preexisting complications. The drug-free pa-
tients (n=18) did not have a significant change in renal 
function or an improvement in hypertension. The most com-
mon benefits were resolution of gingival hyperplasia in two 
children, resolution of infections in 3, resolved lymphoprolif-
erative disorders in 3, and relief of neuropsychiatric com-
plaints in 2. 
Allograft related adverse events. Significant hepatocellU-
lar enzyme elevations (AST, ALT, GGTP) occurred in 44 
(46%) prospectively weaned patients during the study period, 
followed by liver biopsy in 37. The biopsy findings were acute 
cellular rejection (n= 18), minor duct injury (n=3) not severe 
enough to meet the criteria for chronic rejection (see below), 
hepatitis (n=3), normal pathology (n=7), evidence of biliary 
tract obstruction (n=3), nonspecific portal inflammation 
(n=2), and steatosis (n= 1). 
c 
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FIGURE 3. Percent and timing of complete drug withdrawal by base-
line immunosuppression. 
cellular rejections documented in 18 patients (19% of the 
total group) occurred at a mean time of 13.2 months after 
weaning was started, and were graded as mild, moderate, or 
severe (no examples) by histopathologic criteria described in 
detail elsewhere (5). The characteristic mononuclear cell in-
filtrate was mild in most cases, as was reflected by the fact 
that only one recipient had an increase in serum bilirubin. 
There was no significant difference in the laboratory trends 
of AST/ALT/GGTP in the proved rejection (n=18) versus the 
continuous weaning groups (n=37) (Fig. 4, a-c). 
Treatment consisted of pulse steroids and resumption of 
the baseline medication schedules in 15 patients, with 
prompt return of hepatocellular function to normal. The 
other 3 patients. all on CsA-based regimens. were converted 
to TAC therapy because of a moderate acute rejection on 
biopsy, including the one who developed jaundice 29 months 
after all drugs were stopped (Fig. 5). 
OKT3 was not given to any of the 95 patients in the trial. 
One patient developed herpes stomatitis following treatment 
for rejection. Otherwise there were no infectious complica-
tions following resumption of antirejection therapy. 
Uncontirmed acute cellular rejection (n=7, 7%): This 
group included 4 of the 7 patients who did not undergo biopsy 
before intensifying immunosuppression. and 3 whose current 
biopsy revealed only early chronic duct injury that was un-
changed from lindings In the baseline biopsies lbefore wean-
ingl. B~cause there was normalization of liver injury tests 
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FIGURE 4. Mean ALT, AST, and gGTP by rejection and weaning 
groups. 
after the increase of immunosuppression. these 7 cases were 
arbitrarily included in the acute rejection category. 
Suspected chronic rejection (n=3, 3%): This diagnosis. 
which has been defined as the absence of detectable bile 
ducts in =:!50% of the portals triads seen in a biopsy sample or 
the presence of obliterative arteriopathy ( 7). was not made in 
any of the 95 patlents. However. 3 allografts developed sus-
picious de novo histopathologic findings during weaning (Ta-
ble 4), The previous level of immunosuppression was restored 
in two cases. and TAC was started in the third who had been 
weaned from AZA <Table 4), 
Viral hepatitis tn=3. 3%): Two patients developed biopsy 
eVIdence during wearung of recurrent hepatitis attributable 
eo r--- ~f K~f~ : : : :- I 
0 4 • '2 , . 20 2 .... 2. :ao 32 34 
12 
10 
L ](J 8 8 4 2 0 • +¥T f 0 4 8 12 18 20 24 28 30 32 34 
Months Post Wean 
FIGURE 5. Clinical course of OT 1308. 
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f=-~I 
to non-A non-B virus (later shown to be hepatitis C). A third 
recipient whose original disease was biliary atresia, devel-
oped de novo C virus hepatitis infection. Weaning has con-
tinued in these patients with stabilization of liver injury 
tests. 
Recurrent autoimmune disease (n=2): Thirteen patients 
entered the study with diagnosis of PBC. Two (15%), who 
were 7 and 8 years posttransplantation, were diagnosed with 
histopathologically obvious recurrent PBC 7 and 24 months 
after the initiation of weaning. Liver function tests normal-
ized after return to the preexisting CsA-based baseline im-
munosuppression, including PRED. There has been no recur-
rence of autoimmune hepatitis in this series. 
Bile duct obstruction (n=3, 3%): The liver function abnor-
malities in all 3 patients were incorrectly attributed to rejec-
tion and briefly treated as such in 2 cases. Liver enzyme 
values normalized in all 3 recipients after bile duct recon-
struction. Weaning was resumed. 
Previously reported equivocal cases. In our report 2 years 
ago of the first portion of the current prospective series, there 
were 19 liver recipients whose reasons for enzyme elevations 
during weaning were not considered to be unconditionally 
established (3). In the intervening 2 years, 10 of these pa-
tients have had progression of the suspected pathologic pro-
cess (Table 5); 5 have remained unchanged with continuation 
or completion of weaning, one died of pulmonary complica-
tion of cystic fibrosis, and 3 were withdrawn from the proto-
col. 
DISCUSSION 
The ultimate rationale for this trial came from evidence 
that donor/recipient nonreactivity is gradually induced by 
the dissemination from organ allogratls and persistence 
thereafter of donor leukocytes including pluripotent stem 
cells (1,8-12) with ultimate diminution of drug dependence. 
In fact. the majority of the patients entered into the weaning 
trial had been kept at a maintenance treatment level higher 
than needed. Even those who developed rejection during the 
weaning process are currently receiving less average immu-
nosuppression now than at their entry. 
The potential benefits of weaning are too obvious to enu-
merate. However. weaning carries a risk of rejection. which 
was proved to have occurred acutely at some time during or 
J.fter weamng In 18 (19%) of the 85 patients entered. Seven 
-- r 
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TABLE 4. Biopsy evidence arousing suspicion of incipient chronic rejection in 3 cases, and therapeutic response ph 
OT NoJdate of Tx" -BililGGTP (mg%IIU at time Current BiJilGGTP Bx date shOWing Bx findings Drugs at time Current drugs dt: 
of bxJb chronic duct injury of bx re 
64 0.61220 0.31187 3/12196 
2118173 
331 0.61476 0.4/90 2114/95 
9/30/83 
1192 0.8/223 1.21292 217196 
8/5/87 
a Tx=liver transplantation. 
b Bx=liver biopsy. 
Duct not seen Off 
in 4/10 triads 
Duct seen in 25 CsA 
all triads, but 
early damage 
Duct not seen 5 PRED 
in 2110 triads 75 b.i.d. 
CsA 
FK2I2 
50 CyA 
2.5 PRED 
20PRED 
150 b.i.d. 
CsA 
pI 
n( 
b{ 
(oS 
1"l 
rl 
i: 
TABLE 5. Current status after two additional years of 19 previously reported patients (2) who had enzyme elevations during weaning s 
without a definitive explanation I 
OTNo. 
2134 
066SC 
0592 
0440 
1308 
0202 
0235 
64 
0042 
0105 
1464 
0289 
331 
476 
1215 
Diagnosis 
BAb 
NANB hepatitis 
PBC 
A-I-A 
Hepatitis C 
Wilson's disease 
PBC 
BA 
Wilson's disease 
Cryptogenic 
Alcoholic cirrhosis 
NABA hepatitis 
PBC 
Cystic fibrosis 
Halothane 
hepatitis 
Biopsy at first enzyme elevation 
Normal 
Lobular reactivity 
Lobular reactivity 
ND 
Lobular reactivity 
Bile duct obstruction 
ND 
Regenerative hyperplasia 
ND 
Lobular reactivity 
ND 
ND 
Lobular reactivity 
Normal 
ND 
Follow-up therapy (interval) 
Normal 
Hepatitis (23 months) 
ND 
ND 
Moderate ACR (23 months) 
ND 
ND 
Early duct injury (19 
months) 
ND 
ND 
ACR (4 months) 
Hepatitis (6 months) 
Chronic duct injury (8 
months) 
ND 
ND 
Otfdrugs 
Weaning 
On drugs 
On drugs 
Current status" 
On drugs (Fig. 5) 
Off drugs 
Weaning 
On drugs 
Otfdrugs 
Otfdrugs 
Off drugs 
Weaning 
On drugs 
Died during weaning. liver normald 
Off study; pregnancy 
314 BA ND Hepatitis (6 months) Weaning 
474 Hepatitis B Hepatitis ND On drugs 
516 PBC Lobular reactivity Recurrent PBC (15 months) On drugs 
1182 NANB Hepatitis Hepatitis ND On drugs 
a A total of 18 surviving patients are all clinically well with good or completely normal liver function. 
b ND, not done; BA, biliary atresia: PBC, primary biliary cirrhosis; AI-A. alpha-I antitrypsin deficiency. 
C Data on patients who had progression of suspected pathologic process at the time of an earlier report (2), 
d Pulmonary infection associated with cystic fibrosis. 
more cases were arbitrarily placed in the acute rejection 
category without biopsy verification, including 3 in which the 
preweaning biopsy had revealed early duct injury too minor 
to qualify as chronic rejection. Including these 7 patients, 
there was a 25/95 (26%) global incidence of acute rejection 
that occurred from 0.2 to 42 months after starting the wean-
ing. Restoration of immunosuppression to preexisting levels 
resulted in normalization of liver and enzyme elevations in 
15 of the 18 with biopsy proved rejection and all 7 with the 
presumed diagnosis. In the 3 exceptional cases. the rejection 
was histopathologically moderate or severe and one of these 
patients became Jaundiced, with a peak bilirubin of 12 mg%. 
The 3 patients were switched to TAC. We believe that the 
availability of TAC is a prerequisite safety net (13) for a 
weaning trial. 
The circumstances in the patient who developed hyperbil-
irubinemia after rapid weanin'l" from esA. AZA. and PRED 
were similar to those In the weaning senes reported by San-
born et a1. \ 14) in which liver reCIpients were taken olT this 
triple drug therapy at an average 3.1 years posttransplanta-
tion after a minimum one year of stable graft function. As in 
our temporarily jaundiced patient, weaning was done rapidly 
because ofCsA-associated renal failure. Six ofthe 12 patients 
developed rejection, and 2 died (14), 
Chronic rejection was not encountered in our trial, by the 
criteria conventionally used to make this diagnosis (7). How-
ever, when 3 patients developed de novo histopathologic find-
ings suggestive of early chronic rejection, accompanied in one 
case by an acute increase in canalicular enzymes, immuno-
suppression was restored to preexisting levels (n=2) or re-
placed with TAC (n= 1>. Although it is possible that the 
biopsy finding was a sampling variable, the failure to find 
ducts in ~RM% of portal triads may not be adequate as the 
gold standard for this diagnosis (71. One of us (AJ.D.) has 
observed that. when the incipient duct changes are associ-
ated with elevated gamma GTP. the combination frequently 
premomtors chrome rejection. 
Three practical lessons from this expenence deserve em-
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pbasis. One is the necessity for close physician surveillance 
during weaning with frequent assessments of liver function, 
repeat biopsy with the slightest suspicion of rejection, and 
prompt restoration of immunosuppression if this is the diag-
nosis (which it frequently is not). Second, weaning should not 
be as abrupt as was done in the early patients of this series 
(3) or in other trials (14-18). Third, the risk of autoimmune 
recurrence is a real one, as previously predicted (3). Although 
recurrence of autoimmune hepatitis has not yet been ob-
served,2 (15%) of the 13 patients with PBC developed recur-
rence. We have, for the time being, suspended further dose 
reductions in patients with the latter diagnosis. 
With these provisos, we conclude that drug weaning is an 
important management consideration for a large number of 
stable long surviving liver recipients. It was disappointing to 
note that even complete discontinuance of immunosuppres-
sion resulted neither in appreciable recovery of renal func-
tion nor in amelioration of hypertension, underscoring the 
need to reduce if possible the doses of the nephrotoxic T 
cell-directed drugs at an earlier time. However, the long 
term benefits of drug reduction or discontinuation need to be 
assessed on an individual basis, with continual assessment of 
the risk of rejection and need for intervention. Weaning can-
not be safely done unless rescue therapy with TAC is avail-
able. Finally, this experience has confirmed the frequency 
with which late hepatic allograft dysfunction is due to causes 
other than rejection (18, 19). 
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